ClinicalTrials.gg
RecruitingNCT07491146Updated Jul 21, 2026

Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative Pain

A Phase 2 interventional study of Low dose HSK55718 and Medium Dose HSK55718 in Pain After Abdominal Surgery, sponsored by Yingyong Zhou,MD,PhD. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Yingyong Zhou,MD,PhD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Pain with a site in China — 66 open to participants now, 72 under way, 2 of them phase 3. Pain · China.

Planned enrollment
65th of 212
200 · median 120
Started
2026
with 24 others
Phase 2
18 of 247
4 open now
Primary completion
2026-10
later than 26 of 71 live
Registered
225th of 247
by date

Among the 247 studies in Pain with a site in China, this one is the 65th largest by planned enrollment of the 212 interventional ones that give a count, is one of 25 that started in 2026, is one of 18 in phase 2, reaches primary completion later than 26 of the 71 other live ones, and was the 225th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

66 of the 247 studies in Pain with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 66 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Pain with a site in China, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled, and positive-controlled phase II clinical trial was conducted to evaluate the efficacy and safety of HSK55718 injection for postoperative analgesia in patients undergoing abdominal surgery. The primary objective was to evaluate the efficacy of HSK55718 for postoperative analgesia after abdominal surgery. The secondary objective was to evaluate the safety and pharmacokinetic profile of TRD303 solution for postoperative analgesia after abdominal surgery.

03

Conditions studied

  • Pain After Abdominal Surgery

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand, voluntarily participate in this study and sign the ;
  2. Age ≥18 years old, both sexes;
  3. Undergo elective abdominal surgery (open or laparoscopic) with a (estimated) duration of ≥1 hour under general anesthesia;
  4. 18.0 kg/m2≤ (BMI) ≤30.0 kg/m2
  5. (ASA) grade ⅰ-ⅱ;
  6. NRS≥4 in the resting state at any time within 4 hours after the end of surgery;
  7. Be able to comply with the follow-up schedule and other program requirements;
  8. Participants agreed to use highly effective for the entire duration of the study, from the time they signed the ICF until 3 months after the last dose of the product was administered.

Exclusion criteria

Exclusion Criteria:

1. Disease status

  1. History of vestibular dysfunction or dizziness, nausea, retching or vomiting within 1 week before screening;
  2. Cardiovascular history: severe superior vena cava obstruction syndrome, severe pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction within 6 months before screening, or severe arrhythmia such as atrioventricular block of degree Ⅱ or above, or history of class II or above;
  3. Respiratory history: history of severe , acute exacerbation of chronic obstructive pulmonary disease, severe airway stenosis, throat mass, tracheoesophageal fistula or airway tear, and severe respiratory infection within the last 2 weeks before screening;
  4. History of nervous and mental system: history of craniocerebral injury, convulsion, intracranial hypertension, cerebral aneurysm, cerebrovascular accident, ischemic stroke or (TIA); History of schizophrenia, mania, psychosis, long-term use of psychotropic drugs, cognitive dysfunction, etc. Depression, anxiety, epilepsy history, etc.
  5. cancer participants with advanced cancer or extensive ; 2. Laboratory tests during screening meet any of the following criteria:

(1) Blood routine: white blood cell count \< 3.0×109/L; count \< 80×109/L; \< 70 g/L; (2) Coagulation function: (PT) prolongation exceeded the value for 3 seconds; Activated partial thromboplastin time (APTT) prolonged more than 10 seconds; (3) Liver and kidney function: and/or aspartate aminotransferase > 2×ULN; Total > 2×ULN; Serum creatinine > 1.5×ULN; (4) Fasting blood glucose ≥11.1 mmol/L; (5) Participants who did not receive regular antihypertensive treatment or whose blood pressure was poorly controlled (systolic blood pressure ≥160mmHg or ≤90mmHg at screening, and/or diastolic blood pressure ≥100mmHg or ≤60mmHg at screening, excluding abnormalities during anesthesia from admission to PACU and during recovery from anesthesia); (6) >450ms in men and >470ms in women (QTc was calculated with Fridericia's formula); (7) Transcutaneous oxygen saturation (SpO2) \<90% during screening (excluding abnormal anesthesia from admission to PACU and anesthesia recovery period); (8) surface antigen (HBsAg), antibody (HCVAb), syphilis antibody and (HIV) antibody were positive during the screening period; 3. Medication use

  1. Patients with a history of severe drug allergy, or other drugs that may be used during the trial, such as anesthetics propofol/sevoflurane, rocuronium, antiemetic drugs, or drugs and their ;
  2. Taking opioid analgesics for any reason for more than 10 consecutive days within 3 months before randomization;
  3. Drugs that may affect the evaluation of efficacy if the time interval between the last administration of the drug and randomization is less than five half-lives of the drug, including but not limited to the following drugs: Selective α2-adrenoceptor agonists, opioid agonists/antagonists, non-steroidal anti-inflammatory drugs, sedative drugs, monoamine oxidase inhibitors, , antiepileptic, anxiolytic, antidepressant and other antipsychotic drugs. Refer to the list of banned drugs for specific types.
  4. Use of a strong inducer or inhibitor of within 14 days or 5 half-lives before the first dose of the drug, whichever is longer; 4: Others

(1) Having a history of drug abuse, drug abuse and/or alcohol abuse in the past year, with alcohol abuse defined as drinking an average of > 2 units of alcohol per day (1 unit =360mL of 5% beer or 45mL of 40% liquor or 150mL of wine); (2) Positive results of drug abuse screening during the screening period; (3) Pregnant or lactating women; (4) Had participated in other drug clinical trials (defined as receiving investigational drug or placebo) within 3 months before the screening period; (5) Any sensory dysfunction that may interfere with the ability to assess postoperative pain according to the investigator's judgment; (6) Painful physical conditions that may interfere with postoperative evaluation according to the investigator's judgment; (7) Participants had medical complications during the operation and were not suitable for further study according to the investigator's judgment; (8) Participants with any other factors considered by the investigator to be ineligible for the clinical study.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    15mg/7.5mg GHSK55718 group

    After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 15mg was given intravenously, and then 7.5mg HSK55718 injection or normal saline was given intermittently every 6 hours

    Drug: Low dose HSK55718

  • Experimental
    60mg/30mg GHSK55718 group

    After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 60mg was given intravenously, and then30mg HSK55718 injection or normal saline was given intermittently every 6 hours

    Drug: Medium Dose HSK55718

  • Experimental
    120mg/60mg GHSK55718 group

    After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 120mg was given intravenously, and then 60mg HSK55718 injection or normal saline was given intermittently every 6 hours

    Drug: High dose HSK55718

  • Active comparator
    Positive control group

    After the postoperative NRS pain score ≥4, morphine injection 2mg was given intravenously as the first dose, and then morphine injection 2mg was given intermittently every 6 hours

    Drug: Morphine

  • Placebo comparator
    Placebo control group

    After the postoperative NRS pain score ≥4, normal saline was administered intravenously and then intermittently every 6h

    Drug: Normal saline solution

Interventions

  • DrugHSK55718Studies of HSK55718HSK55718 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 15mg was given intravenously, and then 7.5mg HSK55718 injection or normal saline was given intermittently every 6 hours

  • DrugMedium Dose HSK55718

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 60mg was given intravenously, and then 30mg HSK55718 injection or normal saline was given intermittently every 6 hours.

  • DrugHSK55718Studies of HSK55718HSK55718 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 120mg was given intravenously, and then 60mg HSK55718 injection or normal saline was given intermittently every 6 hours

  • NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, morphine injection 2mg was given intravenously as the first dose, and then morphine injection 2mg was given intermittently every 6 hours

  • DrugNormal saline solution

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, normal saline solution was given intravenously as the first dose, and then normal saline solution was given intermittently every 6 hours

06

What researchers measure

Primary outcomes

  1. The time-weighted summed pain intensity differences over 24 h (SPID0-24 h) at rest

    The time-weighted summed pain intensity differences during 0-24 hours (SPID0-24 h) at rest after the first dose

    Time frame: From administration until 24 hours after administration

Secondary outcomes

  1. the time-weighted summed pain intensity differences (SPID) at rest

    The time-weighted summed pain intensity differences during 0-12h, 12-24h, 24-48h, and 0-48h (SPID0-12h、SPID12-24h、SPID24-48h、SPID0-48h) at rest after the first dose

    Time frame: From administration until 12 hours, 48 hours after administration, from 12 hours to 24 hours and 24 hours to 48 hours after administration.

  2. Pain intensity differences (PID)

    The rest pain intensity difference (PID) was calculated at each scoring time point after the first dose, and PID was the difference between the NRS score at each time point and the baseline NRS score

    Time frame: From administration until 48 hours after administration

  3. The proportion of NRS pain score ≤3

    Time frame: From administration until 48 hours after administration

  4. Time to onset

    Time frame: From administration until 12 hours after administration

  5. Cumulative use of rescue analgesics during each period

    Time frame: From the time of administration to 24 hours and 48 hours after administration

  6. Time of first sufentanil rescue analgesia

    Time frame: From administration until 48 hours after administration

  7. Proportion of rescue analgesia

    Time frame: From administration until 48 hours after administration

  8. Postoperative analgesia satisfaction score

    At 24 hours after the end of the study, participants recalled the analgesic effect of the postoperative analgesia and rated their satisfaction on a scale of 0 to 10, with 0 indicating dissatisfied and 10 very satisfied.

    Time frame: From administration until 48 hours after administration

Other outcomes

  1. Maximum Plasma Concentration (Cmax) of HSK55718

    Maximum plasma concentration of HSK55718 after Administration

    Time frame: From administration until 48 hours after administration

  2. Area under curve (AUC) of the plasma concentration-time during 0-∞ (AUC0-∞)

    The total area under the curve (AUC0-∞) at the time of clearance of all prototype drugs from drug administration to day 7 after administration reflects drug absorption and metabolism

    Time frame: From the time of administration to day 7 after administration

  3. Area under curve (AUC) of the plasma concentration-time during 0-t (t=0 to 48h)

    The area under the concentration-time curve (AUC0-t, t= 0-48h) from the beginning of administration to time t, and the absorption and metabolism of the reaction drug over time

    Time frame: From administration until time t (t=0 to 48hours after administration)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2026, 5 months after the start.

Of 125 non-industry phase 2 interventional studies under Pain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 5 months is below that.

Counting every sponsor, half of 187 studies reached it within 21 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 24, 2026
StartActual
May 23, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07491146
Lead sponsor
Yingyong Zhou,MD,PhD
Responsible party
Yingyong Zhou,MD,PhD (PhD, The Third Xiangya Hospital of Central South University) — Sponsor-investigator
First posted
Mar 24, 2026
Start date
May 23, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 21, 2026

Study contacts

Saiying Wang, PhD
Contact
zwyhyll@163.com
+86073188618152

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK55718

Start the discussion